Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma

Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

(2014) Matthew J. Maurer et al.   JOURNAL OF CLINICAL ONCOLOGY

MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma

(2014) C Fernández-Rodríguez et al.   LEUKEMIA

Analysis of FOXO1 mutations in diffuse large B-cell lymphoma

(2013) D. L. Trinh et al.   BLOOD

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

(2012) Z. Y. Xu-Monette et al.   BLOOD

Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma

(2012) Stefano Monti et al.   CANCER CELL

Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies

(2012) Kian-Huat Lim et al.   IMMUNOLOGICAL REVIEWS

Genomic profiling using array comparative genomic hybridization define distinct subtypes of diffuse large b-cell lymphoma: a review of the literature

(2012) Carlos A Tirado et al.   Journal of Hematology & Oncology

Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks?

(2012) S. Barton et al.   ONCOLOGIST

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

(2012) J. G. Lohr et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Aldehyde dehydrogenases and cell proliferation

(2011) G. Muzio et al.   FREE RADICAL BIOLOGY AND MEDICINE

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

(2011) Ryan D. Morin et al.   NATURE

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

(2011) Christian Steidl et al.   NATURE

Analysis of the coding genome of diffuse large B-cell lymphoma

(2011) Laura Pasqualucci et al.   NATURE GENETICS

Endocytosed BCRs sequentially regulate MAPK and Akt signaling pathways from intracellular compartments

(2011) Akanksha Chaturvedi et al.   NATURE IMMUNOLOGY

Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project

(2010) M. Sant et al.   BLOOD

Constitutive Canonical NF-κB Activation Cooperates with Disruption of BLIMP1 in the Pathogenesis of Activated B Cell-like Diffuse Large Cell Lymphoma

(2010) Dinis Pedro Calado et al.   CANCER CELL

BLIMP1 Is a Tumor Suppressor Gene Frequently Disrupted in Activated B Cell-like Diffuse Large B Cell Lymphoma

(2010) Jonathan Mandelbaum et al.   CANCER CELL

Rearrangement ofMYCIs Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab

(2010) Sharon Barrans et al.   JOURNAL OF CLINICAL ONCOLOGY

Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma

(2010) Matthew T. Drake et al.   JOURNAL OF CLINICAL ONCOLOGY

A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling

(2010) Joanne M. Hildebrand et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Early detection of patients with poor risk diffuse large B-cell lymphoma

(2010) Laurie H. Sehn   LEUKEMIA & LYMPHOMA

Oncogenically active MYD88 mutations in human lymphoma

(2010) Vu N. Ngo et al.   NATURE

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

(2010) R. Eric Davis et al.   NATURE

The NF- B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas

(2009) U. Novak et al.   BLOOD

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

(2009) K. J. Savage et al.   BLOOD

The Human Carnitine Transporter SLC22A16 Mediates High Affinity Uptake of the Anticancer Polyamine Analogue Bleomycin-A5

(2009) Mustapha Aouida et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma

(2009) Mara Compagno et al.   NATURE

Mechanisms of change in gene copy number

(2009) P. J. Hastings et al.   NATURE REVIEWS GENETICS

Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP

(2008) L. M. Rimsza et al.   BLOOD

Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study

(2008) K. H. Young et al.   BLOOD

Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

(2008) W Klapper et al.   LEUKEMIA

Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma

(2008) G. Lenz et al.   SCIENCE